查看購物車
  • Simplified Chinese
  • English
  • Japanese
北美鴉片類藥物市場預測至 2030 年 - 區域分析 - 按產品、應用、給藥途徑和配銷通路
市場調查報告書
商品編碼
1637657

北美鴉片類藥物市場預測至 2030 年 - 區域分析 - 按產品、應用、給藥途徑和配銷通路

North America Opioids Market Forecast to 2030 - Regional Analysis - by Product, Application, Route of Administration, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 90 Pages | 訂單完成後即時交付

價格

2022年北美鴉片類藥物市值為49.2189億美元，預計2030年將達到54.4988億美元；預計2022年至2030年複合年成長率為1.3%。

老年人口的增加推動了北美鴉片類藥物市場

大多數老年人患有慢性疼痛，導致日常生活能力下降。老年人普遍患有骨關節疾病、關節炎、癌症和其他引起疼痛的慢性疾病。根據世界衛生組織（WHO）2018年2月的資料，預計到2050年，老年人口資料增加22%，而2015年這一數字為12%。 %。美國、加拿大、英國、法國、德國和日本等已開發國家，以及中國、印度和韓國等發展中國家，老年人口也在經歷顯著成長，這是由於醫療保健設施改善和環境改善所推動的。保健服務；這導致這些地區的預期壽命延長。根據 NCBI 雜誌報道，強效鴉片類藥物處方在老齡化人群中更為普遍，並且在該年齡層中成長速度最快。根據醫療保健研究和品質機構的數據，2020 年至2021 年期間，美國65 歲及以上成年人中平均有12.8% 至少開過一張門診鴉片類藥物處方，4.4% 的人在2020 年至2021 年間開有四種或更多鴉片類藥物處方。此外，符合貧窮類別（6.1%）、低收入類別（6.6%）和中等收入類別（5.2%）資格的老年人比高收入類別（2.6%）的老年人更有可能獲得2020 年至2021 年期間配發四種或更多鴉片類藥物處方。因此，世界各地老年人口的成長推動了北美鴉片類藥物市場的成長。

北美鴉片類藥物市場概況

以鴉片類藥物為基礎的止痛藥是中度至重度關節炎疼痛患者骨科照護的基石。根據美國疾病管制與預防中心 (CDC) 2023 年 10 月發布的關節炎盛行率資料，2019 年至2021 年間，美國近21.2% 的成年人（即5,320 萬人）患有醫生診斷的關節炎，而這一數字預計到 2040 年將達到 7,840 萬人。

另一方面，鴉片類藥物過量案例的激增正在影響北美鴉片類藥物市場的成長。根據世界衛生組織（WHO）關於鴉片類藥物過量的統計數據，2019年美國有70,630人因藥物過量死亡。疾病預防控制中心也估計，1999 年至 2021 年間，該國約有 28 萬人死於處方鴉片類藥物過量。 2021 年，全國所有鴉片類藥物過量死亡中近 21% 涉及處方鴉片類藥物。由於鴉片類藥物過量導致的病例數和死亡率不斷增加，美國疾病管制與預防中心(CDC) 在2017 年將這種情況列為全國性突發公共衛生事件。藥物危機，其中包括過度使用、誤用/濫用的情況迅速增加，以及歸因於鴉片類藥物類別的過量死亡。為了解決鴉片類藥物危機並防止故意濫用，美國食品和藥物管理局 (FDA) 鼓勵開發具有防濫用配方 (ADF) 的處方鴉片類藥物。 FDA 於2021 年3 月批准了酒石酸氫可酮。濫用。此外，為了解決未滿足的醫療需求，美國的藥物核准增加。因此，北美鴉片類藥物市場參與者一直專注於產品批准和改進等策略，以擴大其產品組合，以及擴張和合併以提高其市場佔有率。 2020 年3 月，Trevena, Inc. 的OLINVYK（oliceridine）獲得FDA 批准，這是一種鴉片類激動劑，適用於治療成人中度至重度急性疼痛，特別是當疼痛嚴重到需要靜脈注射鴉片類藥物時。

北美鴉片類藥物市場收入及 2030 年預測（百萬美元）

北美鴉片類藥物市場細分

北美鴉片類藥物市場按產品、應用、給藥途徑、配銷通路和國家分類。

根據產品，北美鴉片類藥物市場分為速釋短效鴉片類藥物和緩釋長效型鴉片類藥物。 2022年，速釋短效鴉片類藥物細分市場佔據了更大的市場佔有率。芬等。緩釋長效型鴉片類藥物進一步細分為羥考酮、芬太尼、嗎啡、美沙酮等。

從應用來看，北美鴉片類藥物市場分為疼痛管理、麻醉、止瀉、止咳、戒癮等。 2022 年，疼痛管理領域佔據最大的市場。

依給藥途徑，北美鴉片類藥物市場分為口服、注射和經皮貼片。 2022 年，口腔細分市場佔據最大的市場。

依配銷通路分類，北美鴉片類藥物市場分為醫院藥房和零售藥房。 2022年，醫院藥局部門將佔據更大的市場佔有率。

按國家/地區分類，北美鴉片類藥物市場分為美國、加拿大和墨西哥。 2022 年，美國在北美鴉片類藥物市場佔有率中佔據主導地位。

Purdue Pharma LP、Endo International plc、Mallinckrodt Plc、Collegium Pharmaceutical Inc、Neuraxpharm Pharmaceuticals SL、Hikma Pharmaceuticals Plc、Rusan Pharma Ltd、Trevena Inc 和 Teva Pharmaceutical Industries Ltd 是北美鴉片類藥物市場的一些領先公司。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 主要見解

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：北美鴉片類藥物市場 - 主要市場動態

  • 北美鴉片類藥物市場 - 主要市場動態
  • 市場促進因素
    • 慢性疼痛發生率激增
    • 老年人口增加
  • 市場限制
    • 藥物濫用增加
  • 市場機會
    • 市場參與者的策略性舉措
  • 未來趨勢
    • 政府措施重點關注開發預防和治療鴉片類藥物過量和疾病的藥物
  • 促進因素和限制的影響：

第 5 章：鴉片類藥物市場 - 北美分析

  • 北美鴉片類藥物市場收入，2020-2030
  • 北美鴉片類藥物市場預測分析

第 6 章：北美鴉片類藥物市場分析 - 按產品

  • 速釋短效鴉片類藥物
  • 緩釋長效型鴉片類藥物

第 7 章：北美鴉片類藥物市場分析 - 按應用

  • 疼痛管理
  • 麻醉
  • 抑制腹瀉
  • 止咳
  • 戒癮
  • 其他

第 8 章：北美鴉片類藥物市場分析 - 按給藥途徑

  • 口服
  • 可注射
  • 經皮貼劑

第 9 章：北美鴉片類藥物市場分析 - 按配銷通路

  • 醫院藥房
  • 零售藥局

第 10 章：北美鴉片類藥物市場 - 國家分析

  • 美國
  • 加拿大
  • 墨西哥

第 11 章：產業格局

  • 概述
  • 鴉片類藥物市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 12 章：公司簡介

  • Purdue Pharma L.P.
  • Endo International plc
  • Mallinckrodt Plc
  • Collegium Pharmaceutical, Inc.
  • Neuraxpharm Pharmaceuticals SL
  • Hikma Pharmaceuticals Plc
  • Rusan Pharma Ltd
  • Trevena, Inc.
  • Teva Pharmaceutical Industries Ltd

第 13 章：附錄

Product Code: BMIRE00031020

The North America opioids market was valued at US$ 4,921.89 million in 2022 and is expected to reach US$ 5,449.88 million by 2030; it is estimated to register a CAGR of 1.3% from 2022 to 2030.

Increasing Geriatric Population Fuels North America Opioids Market

The majority of older people live with chronic pain, resulting in reduced strength to carry out their daily routine. The geriatric population widely suffers from bone and joint disorders, arthritis, cancer, and other chronic disorders causing pain. According to the World Health Organization (WHO) data from February 2018, the geriatric population is estimated to grow by 22% by 2050 compared with 12% in 2015. The data also stated that low- and middle-income countries would account for nearly 80% of this surge. Developed countries such as the US, Canada, the UK, France, Germany, and Japan, and developing countries such as China, India, and South Korea are also experiencing significant growth in the geriatric population, which is driven by improved healthcare facilities and better healthcare services; this has resulted in increased life expectancy in these regions. According to NCBI Journal, strong opioid prescribing is more prevalent in the aging population, growing at the fastest rate in this age group. As per the Agency for Healthcare Research and Quality, 12.8% of adults aged 65 and older, on average, had at least one outpatient opioid prescription, and 4.4% had four or more opioid prescriptions during 2020-2021 in the US. Furthermore, older adults qualifying under the poor category (6.1%), low-income category (6.6%), and middle-income category (5.2%) were more likely than those grouped under the high-income category (2.6%) to get four or more opioid prescription fills during 2020-2021. Thus, the growing geriatric population across the world drives the growth of the North America opioids market.

North America Opioids Market Overview

Opioid-based pain medications are a cornerstone of orthopedic care for patients with moderate to severe arthritis pain. As per data released by the Centers for Disease Control and Prevention (CDC) in October 2023 on arthritis prevalence, nearly 21.2% of adults in the US (i.e., 53.2 million people) had doctor-diagnosed arthritis during 2019-2021, and the number is projected to reach 78.4 million by 2040. The demand for opioids is increasing for pain management with the growing cases of arthritis.

On the other hand, the surging cases of opioid overdose are affecting the growth of the North America opioids market. As per the World Health Organization (WHO) statistics on opioid overdose, there were 70,630 deaths due to drug overdose in 2019 in the US. The CDC also estimated that ~280,000 people in the country died from the overdose of prescription opioids during 1999-2021. In 2021, nearly 21% of all opioid overdose deaths in the country involved a prescription opioid. Due to the increasing number of cases and mortality rate from opioid overdoses, the CDC labeled the situation as a nationwide Public Health Emergency in 2017. This situation was also referred to as the opioid crisis, which included the rapid increase in overuse, misuse/abuse, and overdose deaths attributed to the class of opioid drugs. To tackle the situation of opioid crisis and prevent intentional misuse, the Food and Drug Administration (FDA) is encouraging the development of prescription opioids with abuse-deterrent formulations (ADFs). The FDA approved hydrocodone bitartrate in March 2021. It is the first FDA-approved generic opioid with an ADF, and the medication has properties that are expected to reduce the misuse of the drug when chewed and then taken orally, crushed and snorted, or injected. Further, to address the unmet medical needs, there has been an increase in medication approval in the US. Thus, the North America opioids market players have been focusing on strategies such as product approvals and advancements to broaden their product portfolio, and expansions and mergers to improve their market share. In March 2020, Trevena, Inc. received FDA approval for OLINVYK (oliceridine), an opioid agonist indicated for the management of moderate to severe acute pain in adults, especially when the pain is severe enough to require an intravenous opioid.

North America Opioids Market Revenue and Forecast to 2030 (US$ Million)

North America Opioids Market Segmentation

The North America opioids market is categorized into product, application, route of administration, distribution channel, and country.

Based on product, the North America opioids market is bifurcated immediate release short acting opioid and extended release long acting opioid. The immediate release short acting opioid segment held a larger market share in 2022. The immediate release short acting opioid is further sub segmented into oxycodone, hydrocodone, tramadol, codeine, propoxyphene, and others. The extended release long acting opioid is further sub segmented into oxycodone, fentanyl, morphine, methadone, and others.

In terms of application, the North America opioids market is categorized into pain management, anesthesia, diarrhea suppression, cough suppression, de-addiction, and others. The pain management segment held the largest market share in 2022.

By route of administration, the North America opioids market is segmented into oral, injectable, and transdermal patch. The oral segment held the largest market share in 2022.

By distribution channel, the North America opioids market is bifurcated into hospital pharmacies and retail pharmacies. The hospital pharmacies segment held a larger market share in 2022.

By country, the North America opioids market is segmented into the US, Canada, and Mexico. The US dominated the North America opioids market share in 2022.

Purdue Pharma LP, Endo International plc, Mallinckrodt Plc, Collegium Pharmaceutical Inc, Neuraxpharm Pharmaceuticals SL, Hikma Pharmaceuticals Plc, Rusan Pharma Ltd, Trevena Inc, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the North America opioids market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Opioids Market - Key Market Dynamics

  • 4.1 North America Opioids Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Surging Chronic Pain Incidence
    • 4.2.2 Increasing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 Increasing Drug Abuse
  • 4.4 Market Opportunities
    • 4.4.1 Strategic Initiatives by Market Players
  • 4.5 Future Trends
    • 4.5.1 Government Initiatives Focusing on Development of Medication to Prevent and Treat Opioid Overdose and Disorder
  • 4.6 Impact of Drivers and Restraints:

5. Opioids Market - North America Analysis

  • 5.1 North America Opioids Market Revenue (US$ Million), 2020-2030
  • 5.2 North America Opioids Market Forecast Analysis

6. North America Opioids Market Analysis - by Product

  • 6.1 Immediate Release Short Acting Opioid
    • 6.1.1 Overview
    • 6.1.2 Immediate Release Short Acting Opioid: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.1.2.1 North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
  • 6.2 Extended Release Long-Acting Opioid
    • 6.2.1 Overview
    • 6.2.2 Extended Release Long-Acting Opioid: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.2.2.1 North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid

7. North America Opioids Market Analysis - by Application

  • 7.1 Pain Management
    • 7.1.1 Overview
    • 7.1.2 Pain Management: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Anesthesia
    • 7.2.1 Overview
    • 7.2.2 Anesthesia: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Diarrhea Suppression
    • 7.3.1 Overview
    • 7.3.2 Diarrhea Suppression: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Cough Suppression
    • 7.4.1 Overview
    • 7.4.2 Cough Suppression: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 De-Addiction
    • 7.5.1 Overview
    • 7.5.2 De-Addiction: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Opioids Market Analysis - by Route of Administration

  • 8.1 Oral
    • 8.1.1 Overview
    • 8.1.2 Oral: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.2 Injectable
    • 8.2.1 Overview
    • 8.2.2 Injectable: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Transdermal Patch
    • 8.3.1 Overview
    • 8.3.2 Transdermal Patch: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Opioids Market Analysis - by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Overview
    • 9.1.2 Hospital Pharmacies: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.2 Retail Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Retail Pharmacies: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Opioids Market - Country Analysis

  • 10.1 North America Opioids Market - Country Analysis
    • 10.1.1 North America Opioids Market Breakdown, by Key Countries, 2022 and 2030 (%)
      • 10.1.1.1 North America Opioids Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.1 United States: North America Opioids Market Breakdown, by Product
        • 10.1.1.2.2 United States: North America Opioids Market Breakdown, by Immediate Release Short Acting Opioid
        • 10.1.1.2.3 United States: North America Opioids Market Breakdown, by Extended Release Long-Acting Opioid
        • 10.1.1.2.4 United States: North America Opioids Market Breakdown, by Application
        • 10.1.1.2.5 United States: North America Opioids Market Breakdown, by Route of Administration
        • 10.1.1.2.6 United States: North America Opioids Market Breakdown, by Distribution Channel
      • 10.1.1.3 Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.1 Canada: North America Opioids Market Breakdown, by Product
        • 10.1.1.3.2 Canada: North America Opioids Market Breakdown, by Immediate Release Short Acting Opioid
        • 10.1.1.3.3 Canada: North America Opioids Market Breakdown, by Extended Release Long-Acting Opioid
        • 10.1.1.3.4 Canada: North America Opioids Market Breakdown, by Application
        • 10.1.1.3.5 Canada: North America Opioids Market Breakdown, by Route of Administration
        • 10.1.1.3.6 Canada: North America Opioids Market Breakdown, by Distribution Channel
      • 10.1.1.4 Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.1 Mexico: North America Opioids Market Breakdown, by Product
        • 10.1.1.4.2 Mexico: North America Opioids Market Breakdown, by Immediate Release Short Acting Opioid
        • 10.1.1.4.3 Mexico: North America Opioids Market Breakdown, by Extended Release Long-Acting Opioid
        • 10.1.1.4.4 Mexico: North America Opioids Market Breakdown, by Application
        • 10.1.1.4.5 Mexico: North America Opioids Market Breakdown, by Route of Administration
        • 10.1.1.4.6 Mexico: North America Opioids Market Breakdown, by Distribution Channel

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Opioids Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Purdue Pharma L.P.
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Endo International plc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Mallinckrodt Plc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Collegium Pharmaceutical, Inc.
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Neuraxpharm Pharmaceuticals SL
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Hikma Pharmaceuticals Plc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Rusan Pharma Ltd
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Trevena, Inc.
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Teva Pharmaceutical Industries Ltd
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. North America Opioids Market Segmentation
  • Table 2. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
  • Table 4. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
  • Table 5. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
  • Table 6. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
  • Table 7. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 8. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 9. North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Country
  • Table 10. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
  • Table 11. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
  • Table 12. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
  • Table 13. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
  • Table 14. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 15. United States: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 16. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
  • Table 17. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
  • Table 18. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
  • Table 19. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
  • Table 20. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 21. Canada: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 22. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
  • Table 23. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
  • Table 24. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
  • Table 25. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
  • Table 26. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 27. Mexico: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 28. Recent Organic Growth Strategies in Opioids Market
  • Table 29. Recent Inorganic Growth Strategies in the Opioids Market
  • Table 30. Glossary of Terms, Opioids Market

List Of Figures

  • Figure 1. North America Opioids Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. North America Opioids Market Revenue (US$ Million), 2020-2030
  • Figure 4. North America Opioids Market Share (%) - by Product (2022 and 2030)
  • Figure 5. Immediate Release Short Acting Opioid: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Extended Release Long-Acting Opioid: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. North America Opioids Market Share (%) - by Application (2022 and 2030)
  • Figure 8. Pain Management: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Anesthesia: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Diarrhea Suppression: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Cough Suppression: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. De-Addiction: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Others: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. North America Opioids Market Share (%) - by Route of Administration (2022 and 2030)
  • Figure 15. Oral: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Injectable: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Transdermal Patch: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. North America Opioids Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 19. Hospital Pharmacies: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Retail Pharmacies: North America Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. North America Opioids Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
  • Figure 22. North America Opioids Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 23. United States: North America Opioids Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 24. Canada: North America Opioids Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 25. Mexico: North America Opioids Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 26. Growth Strategies in Opioids Market